Aptamers: Problems, Solutions and Prospects

Лахин, А. В.; Тарантул, В. З.; Генинг, Л. В.

doi:10.32607/20758251-2013-5-4-34-43

Cited by 430 publications

(331 citation statements)

References 108 publications

Supporting

Mentioning

330

Contrasting

Unclassified

Order By: Relevance

“…Further, in a baboon model of venous thrombosis, anti-P-selectin aptamer (ARC5692) has been noted to promote vein recanalization, preserve valve competency, and decrease vein wall fibrosis [115]. Currently, however, such aptamers have not been used clinically, potentially due to challenges with cross-reactivity, interaction with intracellular targets, and degradation[116]. …”

Section: Approaches To Blockade Of Psgl-1/p-selectin Interactionsmentioning

confidence: 99%

Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome

Patel

Miranda-Nieves

Chen

et al. 2017

Translational Research

View full text Add to dashboard Cite

Obesity-induced insulin resistance and metabolic syndrome continue to pose an important public health challenge worldwide as they significantly increase the risk of type 2 diabetes and atherosclerotic cardiovascular disease. Advances in the pathophysiologic understanding of this process has identified that chronic inflammation plays a pivotal role. In this regard, given that both animal models and human studies have demonstrated that the interaction of P-selectin glycoprotein ligand-1 (PSGL-1) with P-selectin are not only critical for normal immune response, but also are upregulated in the setting of metabolic syndrome, PSGL-1/P-selectin interactions provide a novel target for preventing and treating resultant disease. Current approaches of interfering with PSGL-1/P-selectin interactions include targeted antibodies, recombinant immunoglobulins that competitively bind P-selectin, and synthetic molecular therapies. Experimental models as well as clinical trials assessing the role of these modalities in a variety of diseases have continued to contribute to the understanding of PSGL-1/P-selectin interactions and have demonstrated the difficulty in creating clinically relevant therapeutics. Most recently, however, computational simulations have further enhanced our understanding of the structural features of PSGL-1 and related glycomimetics, which are responsible for high affinity selectin interactions. Leveraging these insights for the design of next generation agents has thus led to development of a promising synthetic method for generating PSGL-1 glycosulfopeptide mimetics for the treatment of metabolic syndrome.

show abstract

Section: Approaches To Blockade Of Psgl-1/p-selectin Interactionsmentioning

confidence: 99%

Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome

Patel

Miranda-Nieves

Chen

et al. 2017

Translational Research

View full text Add to dashboard Cite

show abstract

“…2 % w/v DPAP suspensions with different pH (5)(6)(7)(8) were prepared prior to DPAP incubation at 150 rpm. 2 % w/v DPAP suspensions with different pH (5)(6)(7)(8) were prepared prior to DPAP incubation at 150 rpm.…”

Section: Drug Release Profile Of Dpap Formulationmentioning

confidence: 99%

“…[6] The current limitations have incited research interests into the use of biodegradable polymers as delivery vehicles. These include rapid bio-distribution and renal excretion, endonuclease-mediated attack, electrostatic repulsion between negatively charged aptamer and target cell membrane, and undesirable immobilization and complexation of aptamer molecules.…”

Section: Introductionmentioning

confidence: 99%

Design and characterization of a multi‐layered polymeric drug delivery vehicle

et al. 2019

View full text Add to dashboard Cite

Aptamer-mediated targeted delivery is a promising advanced therapeutic delivery strategy with the potential to provide site-directed cyto-toxicity to malignant cells. However, effective translation of preclinical aptamer-navigated targeted delivery data into clinical success has been challenged by several biophysical and biochemical factors including rapid renal clearance, endonuclease-induced degradation, and cell membrane electrostatic repulsion. Aptamer-conjugated biopolymer systems represent new and smart drug carriers capable of delivering adequate amounts of drug molecules sufficient to elicit effective in vivo therapies at target sites in a controlled and sustained drug release pattern. In this work, a novel co-polymeric multi-layer BSA-loaded thrombin aptamer-conjugated PLGA-PEI (DPAP) formulation was synthesized using a w/o/w double emulsion and characterized layer-by-layer in vivo. DLS analysis of the DPAP particles showed a positively charged DPAP particulate system with a D[4,3] average hydrodynamic size of $0.866 mm and a zeta potential of þ9.85 mV. The zeta potential and D[4,3] average hydrodynamic size of DPAP layered compartments demonstrated pH-dependence but are not temperature dependent. The ionic strength of the binding medium affected the degradation and release rates of DPAP micro-particles. A strong binding strength and shielding effect of DPAP towards encapsulated BSA molecules was observed under increasing ionic strength. Thermogravimetric analysis showed that the DPAP formulation decomposes at $300 8C, demonstrating the thermal stability of the polymer composite for effective storage in temperate environments. The data from this study is vital to engineer the interactions between DPAP polymeric system and cellular structures in order to enhance targeting events. While the DPAP construct demonstrates a great potential for targeted delivery, more in vivo delivery work is essential to prove its pre-clinical targeting capability.

show abstract

“…Decay of the oligonucleotide takes from several minutes to several tens of minutes depending on the properties of the oligonucleotide [54]. Although aptamers have high specificity, they also bind to the molecules with similar structure.…”

Section: Limitation Of Aptamer-based Sensormentioning

confidence: 99%

Current and Potential Developments of Cortisol Aptasensing towards Point-of-Care Diagnostics (POTC)

Abidin

Ruslinda

Arshad

et al. 2017

Sensors

View full text Add to dashboard Cite

Anxiety is a psychological problem that often emerges during the normal course of human life. The detection of anxiety often involves a physical exam and a self-reporting questionnaire. However, these approaches have limitations, as the data might lack reliability and consistency upon application to the same population over time. Furthermore, there might be varying understanding and interpretations of the particular question by the participant, which necessitating the approach of using biomarker-based measurement for stress diagnosis. The most prominent biomarker related to stress, hormone cortisol, plays a key role in the fight-or-flight situation, alters the immune response, and suppresses the digestive and the reproductive systems. We have taken the endeavour to review the available aptamer-based biosensor (aptasensor) for cortisol detection. The potential point-of-care diagnostic strategies that could be harnessed for the aptasensing of cortisol were also envisaged.

show abstract

Aptamers: Problems, Solutions and Prospects

Cited by 430 publications

References 108 publications

Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome

Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome

Design and characterization of a multi‐layered polymeric drug delivery vehicle

Current and Potential Developments of Cortisol Aptasensing towards Point-of-Care Diagnostics (POTC)

Contact Info

Product

Resources

About